You are here

Article Text

Article menu

Download PDFPDF

Poster Presentation
Hepatic myeloid-derived suppressor cells in tumor bearing mice exacerbate hepatitis and transform into pro-inflammatory myeloid cells
  1. Jose Medina-Echeverz1,
  2. Tamar Kapanadze1,2,
  3. Chi Ma1,
  4. Austin Duffy1,
  5. Jaba Gamrekelashvili1,2,
  6. Veena Kapoor3,
  7. Jonathan M Weiss4,
  8. Robert H Wiltrout4,
  9. Jay Berzofsky5,
  10. Masaki Terabe5,
  11. Michael P Manns2,
  12. Francesco M Marincola6,
  13. Ena Wang6,
  14. Firouzeh Korangy1,2 and
  15. Tim F Greten1,2
  1. Aff1 grid.94365.3d0000000122975165GI-Malignancy Section, Medical Oncology Branch, National Cancer InstituteNational Institutes of Health Bethesda MD USA
  2. Aff2 grid.10423.340000000095299877Department of Gastroenterology, Hepatology and EndocrinologyHannover Medical School Hannover Germany
  3. Aff3 grid.94365.3d0000000122975165Hematology Branch, National Heart, Lung, and Blood InstituteNational Institutes of Health Bethesda MD USA
  4. Aff4 grid.94365.3d0000000122975165Laboratory of Experimental Immunology, National Cancer InstituteNational Institutes of Health Bethesda MD USA
  5. Aff5 grid.94365.3d0000000122975165Vaccine Branch, National Cancer InstituteNational Institutes of Health Bethesda MD USA
  6. Aff6 grid.410305.30000000121945650Infectious Disease and Immunogenetics Section, Department of Transfusion MedicineClinical Center and trans-NIH Center for Human Immunology, NIH Bethesda MD USA

https://doi.org/10.1186/2051-1426-1-S1-P166

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Myeloid-derived suppressor cells (MDSC) represent a heterogeneous population of immature myeloid cells that accumulate in blood, liver, spleen and tumors upon chronic inflammation and tumor development in patients and mice. Acute hepatitis is characterized by a fast infiltration of inflammatory cells in the liver and increased enzymatic activity at this organ that could lead into liver fibrosis and chirrosis. We have studied the biology of hepatic MDSC in acute hepatitis. Unexpectedly, hepatic MDSC, which accumulate in the liver of mice bearing subcutaneous tumors, failed to suppress inflammatory responses upon Con A injection, but instead were responsible for exacerbating acute liver damage. Phenotypic, genetic and functional studies demonstrated rapid changes of hepatic MDSC from a suppressor phenotype into a pro-inflammatory subset as early as 3 hours after Con A injection. An increase in the expression of pro-inflammatory cytokines, costimulatory molecules such as CD80, CD86 and CD40 along with a loss of suppressor function was noticed in mice upon Con A treatment. These changes were CD40-dependent and not found in CD40-/- MDSC. Interestingly, CD40 ligation of human MDSC in vitro resulted in down-regulation of arginase I expression and suppressor function. Finally, blockade of ROS production in hepatic MDSC ameliorated hepatocyte damage suggesting that MDSC mediated toxicity was ROS dependent. We believe that these findings reflect how MDSC plasticity can be modulated to promote inflammation, opening a new path for therapies targeting innate suppressive cells in cancer patients.